GLP-1 Based Therapy for Adult Obesity

Authored by Open Medicine, published on 2026-08-06 21:29:44.0

The algorithm is broadly aligned with current obesity care: initial assessment, universal lifestyle therapy, eligibility thresholds for anti-obesity medications (AOMs), GLP-1/GIP-GLP-1 agent selection, dose titration, response-based continuation, and consideration of metabolic/bariatric surgery. It appropriately highlights labeled contraindications for GLP-1 RAs and emphasizes monitoring and shared decision-making. Key areas needing nuance are the strength/indication of evidence for some comorbidity-specific claims (e.g., MASLD/MASH, knee OA), and the specific response thresholds/timing which vary by guideline and payer policies.

  1. Evaluate Adults for Obesity and Treatment Eligibility
    Identify Patients Eligible for Obesity Treatment BMI ≥30 or BMI ≥27 plus ≥1 weight-related complication Assess waist circumference Assess obesity complications BMI Screening Classification: Overweight is 25.0–29.9 BMI (kg/m²) Class I obesity is 30.0–34.9 BMI (kg/m²) Class II obesity is 35.0–39.9 BMI (kg/m²) Class III obesity (“severe” obesity) is ≥40
    • Initial Clinical Assessment
      Confirm obesity criteria Assess medical history/meds/family history Evaluate complications & stage Review prior weight-loss efforts Baseline measurements (weight, BP, A1C/fasting glucose, lipids, LFTs, kidney function) Assess contraindications/precautions Patient goals Edmonton Obesity Staging System (EOSS): 0 => No obesity-related risk factors, symptoms, or functional limitations 1 => Mild risk factors or mild symptoms 2 => Established obesity-related chronic disease requiring treatment 3 => Significant end-organ damage, functional impairment, or substantial psychopathology 4 => Severe, potentially end-stage disability from obesity-related disease
      • Evaluate for Secondary Causes and Contributing Factors
        Check for secondary obesity with possible underlying cause such as: Endocrine disorders (e.g. Cushing syndrome, Hypothyroidism) Medications (e.g. Corticosteroids, Antipsychotics) Genetic syndromes (e.g. Prader-Willi syndrome, Bardet-Biedl syndrome)
        • Start Comprehensive Lifestyle Therapy (All patients)
          Calorie-reduced, nutrient-dense eating Physical activity 150–300 min/week + strength Behavioral strategies (self-monitoring, goal setting) Address sleep, stress, alcohol, medications.
          • Eligible for Anti-Obesity Pharmacotherapy?
            Indications: BMI ≥30 or BMI ≥27 with ≥1 weight-related comorbidity If lifestyle alone insufficient, patient prefers additional therapy and no contraindications → consider GLP-1–based therapy.
            • Shared Decision-Making
              Patient preference Insurance coverage Cost Expected weight loss Route of administration
              • Select GLP-1–Based Therapy Based on Clinical Profile and Treatment Goals
                Consider efficacy for weight loss and impact on obesity-related complications. There is no single dominant complication. Choose based on weight-loss efficacy, patient preference, access, side-effect profile, cost, and insurance coverage.
                • Predominant Cardiovascular Disease (ASCVD)
                  Preferred: Semaglutide 2.4 mg weekly (proven MACE benefit).
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                • Type 2 Diabetes
                  Preferred: Semaglutide 2.4 mg weekly OR Tirzepatide weekly (excellent glycemic and weight benefit).
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                • Obstructive Sleep Apnea
                  Preferred: Tirzepatide weekly OR Semaglutide 2.4 mg weekly (improves AHI and quality of life).
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                • MASLD/MASH
                  Preferred: Semaglutide 2.4 mg weekly OR Tirzepatide weekly (improves steatosis and liver inflammation).
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                • Knee Osteoarthritis
                  Preferred: Tirzepatide weekly OR Semaglutide 2.4 mg weekly (reduces pain and improves function).
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                • Chronic Kidney Disease
                  Preferred: Semaglutide 2.4 mg weekly (slows CKD progression and reduces CV risk).
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                • No Predominant Obesity Related Complication
                  Therapy guided by weight-loss efficacy, adverse-effect profile, cost, access and patient preference.
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
          • GLP-1 Contraindications / Use with Caution
            Contraindications: Personal/family history medullary thyroid carcinoma MEN2 Serious hypersensitivity Use with caution: History of pancreatitis Gallbladder disease Severe GI disease (e.g., gastroparesis) Diabetic retinopathy (monitor) Pregnancy/breastfeeding
            • Review Alternative Treatment Options
              Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
              • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                When adequate weight loss not achieved with medications and lifestyle.
          • Discuss Surgery (BMI ≥40 or BMI ≥35 with significant complications)
            Discuss metabolic/bariatric surgery (with or without pharmacotherapy).
            • Shared Decision-Making
              Patient preference Insurance coverage Cost Expected weight loss Route of administration
              • Select GLP-1–Based Therapy Based on Clinical Profile and Treatment Goals
                Consider efficacy for weight loss and impact on obesity-related complications. There is no single dominant complication. Choose based on weight-loss efficacy, patient preference, access, side-effect profile, cost, and insurance coverage.
                • Predominant Cardiovascular Disease (ASCVD)
                  Preferred: Semaglutide 2.4 mg weekly (proven MACE benefit).
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                • Type 2 Diabetes
                  Preferred: Semaglutide 2.4 mg weekly OR Tirzepatide weekly (excellent glycemic and weight benefit).
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                • Obstructive Sleep Apnea
                  Preferred: Tirzepatide weekly OR Semaglutide 2.4 mg weekly (improves AHI and quality of life).
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                • MASLD/MASH
                  Preferred: Semaglutide 2.4 mg weekly OR Tirzepatide weekly (improves steatosis and liver inflammation).
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                • Knee Osteoarthritis
                  Preferred: Tirzepatide weekly OR Semaglutide 2.4 mg weekly (reduces pain and improves function).
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                • Chronic Kidney Disease
                  Preferred: Semaglutide 2.4 mg weekly (slows CKD progression and reduces CV risk).
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                • No Predominant Obesity Related Complication
                  Therapy guided by weight-loss efficacy, adverse-effect profile, cost, access and patient preference.
                  • Initiate and Titrate Semaglutide (Wegovy) – Once Weekly
                    Semaglutide Dose/duration: 0.25 mg 4w; 0.5 mg 4w; 1.0 mg 4w; 1.7 mg 4w; 2.4 mg (maintenance) continue May extend each step up to ≥24w if GI side effects If intolerable persist → consider dose reduction or discontinuation
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
                  • Initiate and Titrate Tirzepatide (Zepbound) – Once Weekly
                    Tirzepatide Dose/duration: 2.5 mg (initial) 4w; 5 mg 4w; 7.5 mg 4w; 10 mg 4w; 12.5 mg 4w; 15 mg (maintenance) continue Increase by 2.5 mg every 4w as tolerated If GI side effects → delay escalation or extend current dose
                    • Monitor and Follow Up (Reassess after ~12 weeks on a maintenance dose)
                      Assess weight/BMI/waist Evaluate efficacy (% weight loss at 3, 6, 12 months) Monitor comorbidities (BP, A1C, lipids, sleep apnea, LFTs, kidney) Assess tolerability/adverse effects Reinforce lifestyle and adherence Common GI Side Effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort Management: Small/low-fat meals Avoid high-fat/high-sugar foods Stay hydrated Consider OTC remedies; Slow dose escalation Usually improves over time
                      • Adequate Response (≥5% weight lost at 3 months or ≥10% at 6 months)
                        Continue current therapy, ongoing lifestyle intervention and monitor every 3–6 months.
                      • Partial Response (<5% weight loss at 3 months or <10% at 6 months)
                        Review adherence/lifestyle, optimize dose escalation, address barriers/comorbidities and reassess in 3 months.
                      • Inadequate Response or Intolerable Side Effects
                        Inadequate weight loss after optimization or unable to tolerate. Consider switch to alternative GLP-1 agent (e.g., semaglutide ↔ tirzepatide) or alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                        • Review Alternative Treatment Options
                          Continue lifestyle interventions while assessing options for alternative therapies. Consider an alternative anti-obesity medication and evaluate for metabolic/bariatric surgery.
                          • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
                            When adequate weight loss not achieved with medications and lifestyle.
            • Consider Surgery (BMI ≥40, or BMI ≥35 with serious comorbidity)
              When adequate weight loss not achieved with medications and lifestyle.
tosprivacyBehavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: USPSTF Recommendation StatementAmerican Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 UpdateAACE/ACE Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity (Update)Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline